<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972488</url>
  </required_header>
  <id_info>
    <org_study_id>CAAA601A22301</org_study_id>
    <secondary_id>2019-001562-15</secondary_id>
    <nct_id>NCT03972488</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET</brief_title>
  <acronym>NETTER-2</acronym>
  <official_title>A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advanced Accelerator Applications</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advanced Accelerator Applications</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of NETTER-2 is to determine if Lutathera in combination with long-acting octreotide&#xD;
      prolongs PFS in GEP-NET patients with high proliferation rate tumors (G2 and G3), when given&#xD;
      as a first line treatment compared to treatment with high dose (60 mg) long-acting&#xD;
      octreotide. Somatostatin analog (SSA) naive patients are eligible, as well as patients&#xD;
      previously treated with SSAs in the absence of progression.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>through Week 72 until 99 PFS events are reached</time_frame>
    <description>Time from randomization to the first line progression (centrally assessed according to RECIST 1.1 or death due to any cause)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>week 16 ±1; week 24 ±1 and then every 12 ±1 weeks until Week 72</time_frame>
    <description>Rate of complete and partial responses (CR, PR) (centrally assessed according to RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Decline (TTD) global health status, diarrhea, fatigue, pain (EORTC QLQ-C30)</measure>
    <time_frame>every 12 ± 1 week from first treatment date until the end of treatment</time_frame>
    <description>TTD by 10 points from baseline in EORTC QLQ-C30 questionnaire: global health status (TTD)-diarrhea (TTD)-fatigue, (TTD)-pain (TTD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Decline (TTD) Total Health Status (EORTC QLQ-G.I.NET21)</measure>
    <time_frame>every 12 ± 1 week from first treatment date until the end of treatment</time_frame>
    <description>TTD by 10 points from baseline in total health status score as measured by EORTC QLQ-G.I.NET21 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>week 16 ±1; week 24 ±1 and then every 12 ±1 weeks until Week 72</time_frame>
    <description>Rate of CR, PR and SD between the two treatment arms (centrally assessed according to RECIST 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>week 16 ±1; week 24 ±1 and then every 12 ±1 weeks until Week 72</time_frame>
    <description>Time from initially meeting the criteria for response (CR or PR) until the time of progression according to RECIST 1.1 or death due to underlying disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>Lutathera: within 2 weeks before infusion and 4 ± 1 weeks after infusion.</time_frame>
    <description>Rate of adverse events between the two treatment arms (scored according to CTCAE grade)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of laboratory toxicities</measure>
    <time_frame>Lutathera: within 2 weeks before infusion and 4 ± 1 weeks after infusion.</time_frame>
    <description>Rate of laboratory toxicities between the two treatment arms (scored according to CTCAE grade)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>up to 4 years from randomization of last patient</time_frame>
    <description>time from randomization date until day of death due to any cause between the two treatment arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Gastro-enteropancreatic Neuroendocrine Tumor</condition>
  <arm_group>
    <arm_group_label>Lutathera plus long-acting octreotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose long-acting octreotide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lutathera</intervention_name>
    <description>7.4 GBq/200 mCi x 4 administrations every 8 +/- 1 weeks</description>
    <arm_group_label>Lutathera plus long-acting octreotide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>long-acting octreotide</intervention_name>
    <description>30 mg every 8 weeks during Lutathera treatment and every 4 weeks after last Lutathera treatment</description>
    <arm_group_label>Lutathera plus long-acting octreotide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose long-acting octreotide</intervention_name>
    <description>60 mg every 4 weeks</description>
    <arm_group_label>high dose long-acting octreotide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optional post-progression re-treatment with Lutathera</intervention_name>
    <description>additional 2-4 cycles of Lutathera (7.4 GBq/200 mCi x 4 cycles)</description>
    <arm_group_label>Lutathera plus long-acting octreotide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optional post-progression cross-over to Lutathera</intervention_name>
    <description>maximum 4 cycles of Lutathera (7.4 GBq/200 mCi x 4 cycles) plus octreotide long-acting (30 mg every 8 weeks)</description>
    <arm_group_label>high dose long-acting octreotide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of metastasized or locally advanced, inoperable (curative intent)&#xD;
             histologically proven, well differentiated Grade 2 or Grade 3 gastroenteropancreatic&#xD;
             neuroendocrine (GEP-NET) tumor diagnosed within 6 months prior to screening.&#xD;
&#xD;
          -  Ki67 index ≥10 and ≤ 55%&#xD;
&#xD;
          -  Patients ≥ 15 years of age and a body weight of &gt; 40 kg at screening&#xD;
&#xD;
          -  Expression of somatostatin receptors on all target lesions documented by CT/MRI scans,&#xD;
             assessed by any of the following somatostatin receptor imaging (SRI) modalities within&#xD;
             3 months prior to randomization: [68Ga]-DOTA-TOC (e.g. Somakit-TOC®) PET/CT (or MRI&#xD;
             when applicable based on target lesions) imaging, [68Ga]-DOTA-TATE PET/CT (or MRI when&#xD;
             applicable based on target lesions) imaging (e.g. NETSPOT®), Somatostatin Receptor&#xD;
             scintigraphy (SRS) with [111In]-pentetreotide (Octreoscan® SPECT/CT), SRS with&#xD;
             [99mTc]-Tektrotyd, [64Cu]-DOTA-TATE PET/CT (or MRI when applicable based on target&#xD;
             lesions) imaging.&#xD;
&#xD;
          -  The tumor uptake observed in the target lesions must be &gt; normal liver uptake.&#xD;
&#xD;
          -  Karnofsky Performance Score (KPS) ≥ 60&#xD;
&#xD;
          -  Presence of at least 1 measurable site of disease&#xD;
&#xD;
          -  Patients who have provided a signed informed consent form to participate in the study,&#xD;
             obtained prior to the start of any protocol related activities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Creatinine clearance &lt; 40 mL/min calculated by the Cockroft Gault method&#xD;
&#xD;
          -  Hb concentration &lt; 5.0 mmol/L (&lt;8.0 g/dL); WBC &lt; 2x10E9/L (2000/mm3); platelets &lt;&#xD;
             75x10E9/L (75x10E3/mm3)&#xD;
&#xD;
          -  Total bilirubin &gt; 3 x ULN&#xD;
&#xD;
          -  Serum albumin &lt; 3.0 g/dL unless prothrombin time is within the normal range&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, are not allowed to participate in this study UNLESS they are using&#xD;
             highly effective methods of contraception throughout the study treatment period&#xD;
             (including cross-over and re-treatment, if applicable) and for 6 months after study&#xD;
             drug discontinuation&#xD;
&#xD;
          -  Peptide receptor radionuclide therapy (PRRT) at any time prior to randomization in the&#xD;
             study.&#xD;
&#xD;
          -  Documented RECIST progression to previous treatments for the current GEP-NET at any&#xD;
             time prior to randomization&#xD;
&#xD;
          -  Patients for whom in the opinion of the investigator other therapeutic options (eg&#xD;
             chemo-, targeted therapy) are considered more appropriate than therapy offered in the&#xD;
             study, based on patient and disease characteristics&#xD;
&#xD;
          -  Any previous therapy with Interferons, Everolimus (mTOR-inhibitors), chemotherapy or&#xD;
             other systemic therapies for GEP-NET administered for more than 1 month or within 12&#xD;
             weeks prior to randomization in the study.&#xD;
&#xD;
          -  Any previous radioembolization, chemoembolization and radiofrequency ablation for&#xD;
             GEP-NET&#xD;
&#xD;
          -  Any surgery within 12 weeks prior to randomization in the study&#xD;
&#xD;
          -  Known brain metastases, unless these metastases have been treated and stabilized for&#xD;
             at least 24 weeks, prior to screening in the study. Patients with a history of brain&#xD;
             metastases must have a head CT or MRI with contrast to document stable disease prior&#xD;
             to randomization in the study.&#xD;
&#xD;
          -  Uncontrolled congestive heart failure (NYHA II, III, IV). Patients with history of&#xD;
             congestive heart failure who do not violate this exclusion criterion will undergo an&#xD;
             evaluation of their cardiac ejection fraction prior to randomization via&#xD;
             echocardiography. The results from an earlier assessment (not exceeding 30 days prior&#xD;
             to randomization) may substitute the evaluation at the discretion of the Investigator,&#xD;
             if no clinical worsening is noted. The patient's measured cardiac ejection fraction in&#xD;
             these patients must be ≥40% before randomization.&#xD;
&#xD;
          -  QTcF &gt; 470 msec for females and QTcF &gt; 450 msec for males or congenital long QT&#xD;
             syndrome&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus as defined by hemoglobin A1c value &gt; 7.5%&#xD;
&#xD;
          -  Hyperkaleamia &gt; 6.0 mmol/L (CTCAE Grade 3) which is not corrected prior to study&#xD;
             enrolment&#xD;
&#xD;
          -  Any patient receiving treatment with short-acting octreotide, which cannot be&#xD;
             interrupted for 24 h before and 24 h after the administration of Lutathera, or any&#xD;
             patient receiving treatment with SSAs (e.g. octreotide long-acting), which cannot be&#xD;
             interrupted for at least 6 weeks before the administration of Lutathera.&#xD;
&#xD;
          -  Patients with any other significant medical, psychiatric, or surgical condition,&#xD;
             currently uncontrolled by treatment, which may interfere with the completion of the&#xD;
             study.&#xD;
&#xD;
          -  Prior external beam radiation therapy to more than 25% of the bone marrow.&#xD;
&#xD;
          -  Current spontaneous urinary incontinence&#xD;
&#xD;
          -  Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in&#xD;
             situ of the uterine cervix, unless definitively treated and proven no evidence of&#xD;
             recurrence for 5 years&#xD;
&#xD;
          -  Patient with known incompatibility to CT Scans with IV contrast due to allergic&#xD;
             reaction or renal insufficiency. If such a patient can be imaged with MRI, then the&#xD;
             patient would not be excluded.&#xD;
&#xD;
          -  Hypersensitivity to any somatostatin analogues, the IMPs active substance or to any of&#xD;
             the excipients.&#xD;
&#xD;
          -  Patients who have participated in any therapeutic clinical study/received any&#xD;
             investigational agent within the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novarits.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>USF - H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jonathan Strosberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics - Oncology</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Bushnell, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Oncology</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thorvardur Halfdanarson, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Halperin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre, University of Western Ontario - Oncology</name>
      <address>
        <city>London</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Laidley, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sir Mortimer B Davis/Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Petr Kavan, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francois-Alexandre Buteau, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sten Myrehaug</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BC Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jonathan Loree</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Paris Nord-Val de Seine</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Philippe Ruszniewski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon (HCL) - Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Catherine Lombard-Bohas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier - Oncology</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emmanuel Deshayes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Baudin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marianne Pavel, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen - Klinik für Nuklearmedizin</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ken Hermann, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.di Bologna Policl.S.Orsola</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Davide Campana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Genova - Oncology</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Diego Ferone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Romagnolo</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefano Severi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Irccs Istituto Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ettore Seregni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ieo, Irccs</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicola Fazio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS fondazione Pascale - Oncology</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Salvatore Tafuto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova, Reggio Emilia - Oncology</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Annibale Versari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'Andrea - Università La Sapienza U.O.C. Mal App. Digerente e - Oncology</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Panzuto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-Si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jin Won Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center - Oncology</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Baek-Yeol Ryoo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital - Department of Internal Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Do-Youn Oh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System - Medical Oncology</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sang Joon Shin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Myung-Ah Lee, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Johannes Hofland</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht - Oncology</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marnix Lam, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jaume Capdevila Castillón</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Montserrat Blanco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Teresa Alonso Gordoa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Angel Segura Huerta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen Falk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guys And St Thomas Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Valerie Lewington, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital - Oncology</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rajaventhan Srirajaskanthan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital, London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Shaunak Navalkissoor, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jonathan Wadsley, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Lutetium Lu 177 dotatate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

